Health ❯ Pharmaceuticals ❯ Obesity Treatment ❯ GLP-1 Medicines

Oral Medications

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.